Patents

Scandion Oncology has a strong patent portfolio lasting until 2037.

We believe our patents are attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

We have taken steps to secure our patents:

Published

PCT/EP2017/061823
SCO-101 in combination with an anti-cancer agent for the treatment of cancer

Specific combination therapies include:

  • SCO-101 + specific topoisomerase I inhibitors (granted in Europe)
  • SCO-101 + taxanes
  • SCO-101 + anti-oestrogens

Granted : Europe
Pending : Australia, Brazil, Canada, China, Europe (divisional), India, Japan, United States


PCT/EP2019/073796
SCO-101 for treatment of subjects with elevated expression or activity of SRPK1


PCT/EP2019/078044
This PCT application relates to treatment, amelioration and/or prevention of a microbial infection.


PCT/DE2007/001104
SCO-201 and related compounds

Granted : Australia, Canada, Europe, Japan, United States
Pending : Brazil


PCT/EP2012/070403
SCO-201

Granted: Australia, Japan, United States
Pending: Brazil, Canada, Europe


PCT/EP2016/053843
SCO-201 and related compound for treatment of cancer and HIV infections

Granted: Europe
Pending:
Australia, Brazil, Japan, United States

Not published

Patent agency
HØIBERG
hoiberg.com

Janni Wandahl Pedersen
Partner

European Patent Attorney, CDPA
PhD (Molecular Cell Biology),
MSc (Human Biology)

Patent agency
HØIBERG
hoiberg.com

Kasper Fjelbye

Patent Advisor
PhD (Pharmaceutical Sciences),
MSc (Medicinal Chemistry)

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union